
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc has demonstrated strong performance in console sales for Q3, surpassing expectations despite a delay in one major order, which is anticipated to contribute to the company's path to profitability. The company is actively pursuing cost reduction and manufacturing efficiency initiatives while aiming for a gross margin milestone of 50%, supported by an adj. gross margin of 39.8% that exceeds both consensus estimates and prior guidance. Furthermore, the accelerating consumables ordering and the expanding average order size indicate robust market traction for the Tablo system, positioning Outset Medical favorably within the under-penetrated dialysis market.
Bears say
Outset Medical Inc has lowered its full-year revenue guidance by approximately $7 million, reflecting ongoing delays in enterprise deal timing and weaker-than-expected consumables revenue due to reduced orders from acute care customers. The company's total revenues fell to $29.4 million, below both its prior estimates and consensus expectations, primarily due to delayed recognition of console orders and the anticipated slip of major deals into 2026. Additionally, the recent departure of the head of sales may further disrupt sales efforts during a critical period, contributing to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares